Improving Cancer Treatment by Targeting Immune Cells
CD200R blockade for cancer immunotherapy
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11159719
This research explores a new way to help your immune system fight advanced cancer by focusing on specific cells that can either help or hurt the body's defense.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11159719 on ClinicalTrials.gov |
What this research studies
Current cancer treatments often focus on reactivating T cells, a type of immune cell, to destroy tumors. However, many tumors also contain other immune cells, called myeloid cells, which can either fight cancer or help it grow. This project aims to understand how a specific signal, called CD200R, affects both T cells and myeloid cells within tumors. By learning more about how CD200R works, we hope to develop new and more effective immunotherapies that target a broader range of immune cells to better fight advanced cancers.
Who could benefit from this research
Good fit: Patients with advanced cancers, particularly those whose tumors involve specific immune cell interactions, might be ideal candidates for future treatments based on this research.
Not a fit: Patients whose cancer does not involve the CD200R pathway or specific immune cell types targeted by this research may not directly benefit.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective immunotherapy options for patients with advanced cancers.
How similar studies have performed: Clinical trials are already exploring antibody treatments that block this pathway, suggesting a foundation for this approach, though the detailed understanding of its mechanism is still developing.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BASU, SUJIT — OHIO STATE UNIVERSITY
- Study coordinator: BASU, SUJIT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer